Robert Wolfe
Concepts (637)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscle Proteins | 89 | 2024 | 343 | 13.090 |
Why?
| | Dietary Proteins | 50 | 2025 | 247 | 12.540 |
Why?
| | Muscle, Skeletal | 110 | 2024 | 799 | 12.520 |
Why?
| | Amino Acids, Essential | 49 | 2024 | 136 | 9.830 |
Why?
| | Amino Acids | 62 | 2025 | 386 | 8.520 |
Why?
| | Protein Biosynthesis | 28 | 2021 | 267 | 4.820 |
Why?
| | Dietary Supplements | 33 | 2024 | 470 | 4.100 |
Why?
| | Nutritional Requirements | 18 | 2025 | 68 | 3.960 |
Why?
| | Burns | 28 | 2022 | 163 | 3.930 |
Why?
| | Exercise | 29 | 2024 | 559 | 3.240 |
Why?
| | Aging | 27 | 2020 | 722 | 3.170 |
Why?
| | Diet | 15 | 2024 | 591 | 3.110 |
Why?
| | Phenylalanine | 49 | 2022 | 139 | 3.110 |
Why?
| | Triglycerides | 18 | 2020 | 171 | 3.100 |
Why?
| | Proteins | 15 | 2022 | 353 | 2.840 |
Why?
| | Sarcopenia | 10 | 2022 | 99 | 2.840 |
Why?
| | Milk Proteins | 10 | 2016 | 77 | 2.810 |
Why?
| | Isotopes | 6 | 2022 | 26 | 2.760 |
Why?
| | Insulin | 38 | 2022 | 485 | 2.500 |
Why?
| | Glucose | 18 | 2022 | 356 | 2.430 |
Why?
| | Meals | 12 | 2022 | 58 | 2.320 |
Why?
| | Insulin Resistance | 18 | 2024 | 281 | 2.190 |
Why?
| | Humans | 212 | 2025 | 52441 | 2.090 |
Why?
| | Leucine | 14 | 2023 | 116 | 2.020 |
Why?
| | Bed Rest | 15 | 2020 | 36 | 2.010 |
Why?
| | Body Composition | 27 | 2022 | 343 | 1.930 |
Why?
| | Anabolic Agents | 7 | 2019 | 41 | 1.920 |
Why?
| | Digestion | 5 | 2020 | 29 | 1.910 |
Why?
| | Kinetics | 31 | 2022 | 613 | 1.850 |
Why?
| | Liver | 12 | 2021 | 1150 | 1.840 |
Why?
| | Energy Intake | 11 | 2024 | 183 | 1.830 |
Why?
| | Male | 145 | 2024 | 26874 | 1.740 |
Why?
| | Blood Glucose | 30 | 2020 | 483 | 1.730 |
Why?
| | Skin | 10 | 2015 | 416 | 1.670 |
Why?
| | Energy Metabolism | 19 | 2024 | 315 | 1.570 |
Why?
| | Aged | 65 | 2024 | 10242 | 1.560 |
Why?
| | Resistance Training | 11 | 2024 | 102 | 1.500 |
Why?
| | Weight Loss | 6 | 2018 | 257 | 1.500 |
Why?
| | Nutrition Policy | 7 | 2012 | 39 | 1.440 |
Why?
| | Obesity | 13 | 2024 | 1176 | 1.430 |
Why?
| | Rabbits | 22 | 2015 | 370 | 1.420 |
Why?
| | Palmitates | 7 | 2022 | 28 | 1.390 |
Why?
| | Feeding Behavior | 7 | 2020 | 189 | 1.370 |
Why?
| | Female | 111 | 2024 | 28277 | 1.310 |
Why?
| | Muscle Strength | 13 | 2024 | 132 | 1.290 |
Why?
| | Animals | 53 | 2024 | 13485 | 1.290 |
Why?
| | Carbon Isotopes | 22 | 2017 | 71 | 1.260 |
Why?
| | Lipid Metabolism | 7 | 2020 | 189 | 1.250 |
Why?
| | Arginine | 9 | 2022 | 183 | 1.240 |
Why?
| | Leg | 21 | 2011 | 122 | 1.230 |
Why?
| | Adult | 79 | 2024 | 14205 | 1.230 |
Why?
| | Postprandial Period | 11 | 2024 | 75 | 1.220 |
Why?
| | Hyperinsulinism | 6 | 2015 | 30 | 1.210 |
Why?
| | Wound Healing | 6 | 2008 | 223 | 1.160 |
Why?
| | Models, Biological | 13 | 2024 | 735 | 1.150 |
Why?
| | Dietary Carbohydrates | 11 | 2024 | 91 | 1.140 |
Why?
| | Double-Blind Method | 17 | 2021 | 726 | 1.140 |
Why?
| | Fatty Acids, Nonesterified | 10 | 2020 | 39 | 1.130 |
Why?
| | Heart Failure | 3 | 2019 | 527 | 1.070 |
Why?
| | Wounds and Injuries | 6 | 2008 | 300 | 1.000 |
Why?
| | Food, Formulated | 4 | 2019 | 41 | 0.990 |
Why?
| | Hypoglycemic Agents | 7 | 2013 | 223 | 0.940 |
Why?
| | Middle Aged | 59 | 2024 | 13133 | 0.930 |
Why?
| | Valerates | 3 | 2017 | 39 | 0.910 |
Why?
| | Critical Illness | 8 | 2016 | 306 | 0.890 |
Why?
| | Isotope Labeling | 4 | 2019 | 59 | 0.890 |
Why?
| | Overweight | 4 | 2018 | 230 | 0.820 |
Why?
| | Swine | 8 | 2019 | 428 | 0.820 |
Why?
| | Cross-Over Studies | 13 | 2022 | 236 | 0.810 |
Why?
| | Pyruvic Acid | 3 | 2021 | 20 | 0.790 |
Why?
| | Amino Acids, Branched-Chain | 3 | 2017 | 43 | 0.770 |
Why?
| | Hyperglycemia | 6 | 2020 | 88 | 0.750 |
Why?
| | Mitochondria, Muscle | 6 | 2024 | 40 | 0.740 |
Why?
| | Nitric Oxide | 4 | 2015 | 238 | 0.740 |
Why?
| | Geriatric Assessment | 2 | 2021 | 109 | 0.730 |
Why?
| | Whole Body Imaging | 2 | 2019 | 22 | 0.710 |
Why?
| | Food Analysis | 1 | 2021 | 28 | 0.700 |
Why?
| | Kidney | 2 | 2021 | 716 | 0.690 |
Why?
| | Deuterium | 11 | 2019 | 47 | 0.690 |
Why?
| | Gluconeogenesis | 1 | 2020 | 4 | 0.690 |
Why?
| | Lactic Acid | 2 | 2021 | 79 | 0.680 |
Why?
| | Actinidia | 1 | 2020 | 8 | 0.670 |
Why?
| | Glycolysis | 1 | 2021 | 70 | 0.670 |
Why?
| | Hydrocortisone | 8 | 2020 | 112 | 0.660 |
Why?
| | Muscular Atrophy | 4 | 2021 | 73 | 0.650 |
Why?
| | Food, Fortified | 2 | 2021 | 27 | 0.630 |
Why?
| | Muscle Contraction | 5 | 2019 | 109 | 0.630 |
Why?
| | Aged, 80 and over | 13 | 2021 | 3449 | 0.630 |
Why?
| | Lipoproteins, VLDL | 3 | 2004 | 7 | 0.630 |
Why?
| | Caloric Restriction | 3 | 2020 | 35 | 0.630 |
Why?
| | Renal Dialysis | 9 | 2015 | 189 | 0.620 |
Why?
| | Metformin | 3 | 2005 | 82 | 0.600 |
Why?
| | Elder Nutritional Physiological Phenomena | 2 | 2015 | 7 | 0.600 |
Why?
| | Human Growth Hormone | 2 | 2017 | 49 | 0.590 |
Why?
| | DNA | 4 | 2007 | 544 | 0.590 |
Why?
| | Stress, Physiological | 4 | 2019 | 183 | 0.590 |
Why?
| | Nutritional Status | 6 | 2021 | 146 | 0.580 |
Why?
| | Beverages | 4 | 2019 | 58 | 0.580 |
Why?
| | Regional Blood Flow | 10 | 2015 | 109 | 0.570 |
Why?
| | Muscle Cells | 4 | 2009 | 20 | 0.570 |
Why?
| | Adrenergic beta-Antagonists | 5 | 2006 | 107 | 0.570 |
Why?
| | Sepsis | 6 | 2019 | 236 | 0.570 |
Why?
| | Young Adult | 17 | 2024 | 4346 | 0.560 |
Why?
| | Diabetes Mellitus | 2 | 2020 | 318 | 0.560 |
Why?
| | Critical Care | 2 | 2017 | 213 | 0.550 |
Why?
| | Lipids | 7 | 2022 | 163 | 0.540 |
Why?
| | Glucose Intolerance | 4 | 2020 | 27 | 0.540 |
Why?
| | Cardiovascular Diseases | 4 | 2021 | 493 | 0.530 |
Why?
| | Chromatography, High Pressure Liquid | 4 | 2007 | 333 | 0.530 |
Why?
| | Fenofibrate | 2 | 2007 | 17 | 0.530 |
Why?
| | Hypolipidemic Agents | 2 | 2007 | 30 | 0.530 |
Why?
| | Eating | 9 | 2024 | 158 | 0.520 |
Why?
| | Time Factors | 18 | 2021 | 2987 | 0.520 |
Why?
| | Skin Transplantation | 3 | 2007 | 43 | 0.520 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 3 | 2005 | 64 | 0.500 |
Why?
| | Kidney Failure, Chronic | 7 | 2015 | 205 | 0.500 |
Why?
| | Fatty Acids | 6 | 2013 | 152 | 0.490 |
Why?
| | Weight Lifting | 3 | 2004 | 29 | 0.490 |
Why?
| | Homeostasis | 3 | 2014 | 206 | 0.480 |
Why?
| | Proteolysis | 5 | 2020 | 100 | 0.480 |
Why?
| | Cardiovascular Agents | 1 | 2015 | 65 | 0.460 |
Why?
| | Citrulline | 1 | 2015 | 98 | 0.460 |
Why?
| | Diet, Reducing | 1 | 2015 | 39 | 0.450 |
Why?
| | Epidermis | 2 | 2006 | 32 | 0.440 |
Why?
| | Nutritional Support | 1 | 2014 | 31 | 0.440 |
Why?
| | Zinc | 2 | 2022 | 57 | 0.440 |
Why?
| | Metabolomics | 1 | 2016 | 147 | 0.440 |
Why?
| | Testosterone | 5 | 2007 | 145 | 0.440 |
Why?
| | Ileum | 3 | 2019 | 87 | 0.430 |
Why?
| | Adipose Tissue | 4 | 2013 | 205 | 0.420 |
Why?
| | Protein Stability | 2 | 2017 | 45 | 0.420 |
Why?
| | Gas Chromatography-Mass Spectrometry | 4 | 2016 | 69 | 0.420 |
Why?
| | Administration, Oral | 9 | 2009 | 455 | 0.420 |
Why?
| | Up-Regulation | 1 | 2015 | 462 | 0.420 |
Why?
| | Radiopharmaceuticals | 1 | 2014 | 198 | 0.410 |
Why?
| | Nitrogen Isotopes | 7 | 2022 | 39 | 0.400 |
Why?
| | Biological Availability | 4 | 2019 | 107 | 0.400 |
Why?
| | Muscle Development | 1 | 2013 | 24 | 0.400 |
Why?
| | PPAR alpha | 3 | 2007 | 61 | 0.390 |
Why?
| | Infusions, Intravenous | 9 | 2021 | 212 | 0.390 |
Why?
| | Body Mass Index | 13 | 2022 | 701 | 0.390 |
Why?
| | Frail Elderly | 1 | 2012 | 35 | 0.390 |
Why?
| | Activities of Daily Living | 2 | 2014 | 185 | 0.380 |
Why?
| | Biopsy | 9 | 2011 | 594 | 0.380 |
Why?
| | Palmitoyl Coenzyme A | 4 | 2015 | 4 | 0.380 |
Why?
| | Glutamine | 2 | 2003 | 177 | 0.370 |
Why?
| | Adolescent | 22 | 2020 | 6713 | 0.360 |
Why?
| | Fibroblasts | 2 | 2004 | 357 | 0.360 |
Why?
| | Glycerol | 4 | 2009 | 19 | 0.360 |
Why?
| | Nutritional Physiological Phenomena | 4 | 2018 | 22 | 0.360 |
Why?
| | Oxidation-Reduction | 8 | 2024 | 327 | 0.360 |
Why?
| | Mitochondria | 4 | 2024 | 420 | 0.350 |
Why?
| | Hormones | 5 | 2019 | 57 | 0.350 |
Why?
| | Extracellular Fluid | 3 | 2006 | 14 | 0.340 |
Why?
| | Phospholipids | 2 | 2020 | 57 | 0.340 |
Why?
| | Threonine | 3 | 2022 | 15 | 0.340 |
Why?
| | Arthroplasty, Replacement, Hip | 2 | 2021 | 268 | 0.340 |
Why?
| | Metabolism | 5 | 2020 | 25 | 0.330 |
Why?
| | Heart Rate | 3 | 2007 | 311 | 0.330 |
Why?
| | Physical Endurance | 3 | 2024 | 35 | 0.330 |
Why?
| | Hospitalization | 3 | 2012 | 731 | 0.330 |
Why?
| | Nitrogen | 5 | 2022 | 70 | 0.330 |
Why?
| | Immobilization | 2 | 2007 | 15 | 0.320 |
Why?
| | Cytokines | 4 | 2007 | 622 | 0.320 |
Why?
| | Nutritive Value | 3 | 2017 | 29 | 0.310 |
Why?
| | Muscular Diseases | 3 | 2006 | 60 | 0.310 |
Why?
| | Body Weight | 7 | 2025 | 524 | 0.310 |
Why?
| | Biological Transport | 8 | 2013 | 153 | 0.310 |
Why?
| | Cardiac Output | 2 | 2006 | 32 | 0.310 |
Why?
| | Propanolamines | 2 | 2006 | 13 | 0.300 |
Why?
| | Urea | 4 | 2022 | 80 | 0.300 |
Why?
| | Lung Compliance | 2 | 2006 | 9 | 0.300 |
Why?
| | Models, Animal | 4 | 2016 | 230 | 0.300 |
Why?
| | Musculoskeletal Physiological Phenomena | 2 | 2013 | 7 | 0.290 |
Why?
| | Hypertriglyceridemia | 1 | 2008 | 19 | 0.290 |
Why?
| | Propranolol | 3 | 2006 | 76 | 0.290 |
Why?
| | Area Under Curve | 6 | 2008 | 182 | 0.290 |
Why?
| | Blood Flow Velocity | 6 | 2007 | 97 | 0.290 |
Why?
| | Diet, Carbohydrate-Restricted | 2 | 2018 | 11 | 0.290 |
Why?
| | Fibrinogen | 2 | 2005 | 31 | 0.290 |
Why?
| | Case-Control Studies | 7 | 2010 | 1202 | 0.290 |
Why?
| | Diet, Protein-Restricted | 3 | 2024 | 9 | 0.280 |
Why?
| | Protein Processing, Post-Translational | 1 | 2009 | 152 | 0.280 |
Why?
| | Protein Kinase C | 1 | 2008 | 72 | 0.280 |
Why?
| | Reproducibility of Results | 6 | 2016 | 1223 | 0.280 |
Why?
| | Soft Tissue Injuries | 1 | 2008 | 17 | 0.280 |
Why?
| | RNA, Transfer, Amino Acyl | 1 | 2007 | 1 | 0.280 |
Why?
| | Intracellular Fluid | 2 | 2005 | 12 | 0.280 |
Why?
| | Hemoglobins | 2 | 2006 | 114 | 0.280 |
Why?
| | Treatment Outcome | 15 | 2020 | 5508 | 0.280 |
Why?
| | Absorptiometry, Photon | 5 | 2020 | 161 | 0.270 |
Why?
| | Alanine | 3 | 2004 | 43 | 0.270 |
Why?
| | Acetates | 1 | 2007 | 51 | 0.270 |
Why?
| | Insulin, Long-Acting | 1 | 2007 | 2 | 0.270 |
Why?
| | Child | 19 | 2022 | 7194 | 0.260 |
Why?
| | Intermittent Claudication | 1 | 2007 | 16 | 0.260 |
Why?
| | Herpesvirus 4, Human | 1 | 2007 | 43 | 0.260 |
Why?
| | Carbon Dioxide | 1 | 2007 | 95 | 0.260 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2009 | 1365 | 0.260 |
Why?
| | Peripheral Vascular Diseases | 1 | 2007 | 22 | 0.260 |
Why?
| | Virus Activation | 1 | 2007 | 39 | 0.260 |
Why?
| | Pseudomonas Infections | 2 | 2017 | 55 | 0.260 |
Why?
| | Acyl Coenzyme A | 2 | 2006 | 8 | 0.260 |
Why?
| | Muscles | 2 | 2006 | 108 | 0.260 |
Why?
| | Malnutrition | 3 | 2021 | 89 | 0.260 |
Why?
| | Creatine | 2 | 2016 | 39 | 0.250 |
Why?
| | Carnitine | 2 | 2010 | 67 | 0.250 |
Why?
| | Hemodynamics | 2 | 2017 | 235 | 0.250 |
Why?
| | Dermis | 2 | 2004 | 19 | 0.250 |
Why?
| | Mafenide | 1 | 2006 | 1 | 0.250 |
Why?
| | Adrenergic beta-1 Receptor Antagonists | 1 | 2006 | 7 | 0.250 |
Why?
| | Valine | 2 | 2003 | 57 | 0.250 |
Why?
| | Living Donors | 1 | 2006 | 27 | 0.250 |
Why?
| | Military Personnel | 2 | 2019 | 175 | 0.240 |
Why?
| | Hormone Replacement Therapy | 1 | 2005 | 25 | 0.240 |
Why?
| | Mitochondrial Proteins | 3 | 2022 | 91 | 0.240 |
Why?
| | Shock, Hemorrhagic | 1 | 2005 | 13 | 0.230 |
Why?
| | Brain Injuries | 1 | 2007 | 158 | 0.230 |
Why?
| | Mitochondrial Dynamics | 3 | 2024 | 22 | 0.230 |
Why?
| | Models, Theoretical | 2 | 2016 | 181 | 0.230 |
Why?
| | Walkers | 1 | 2004 | 2 | 0.230 |
Why?
| | Blood Coagulation | 1 | 2005 | 64 | 0.230 |
Why?
| | PPAR delta | 1 | 2024 | 2 | 0.220 |
Why?
| | Dynamins | 1 | 2024 | 9 | 0.220 |
Why?
| | Physical Conditioning, Animal | 2 | 2024 | 64 | 0.220 |
Why?
| | Caseins | 1 | 2004 | 78 | 0.220 |
Why?
| | Glucose Clamp Technique | 5 | 2009 | 15 | 0.220 |
Why?
| | Malonyl Coenzyme A | 2 | 2010 | 7 | 0.220 |
Why?
| | Exercise Tolerance | 1 | 2004 | 42 | 0.220 |
Why?
| | Physical Exertion | 1 | 2004 | 45 | 0.220 |
Why?
| | Metabolic Clearance Rate | 5 | 2019 | 66 | 0.210 |
Why?
| | Child, Preschool | 10 | 2022 | 4046 | 0.210 |
Why?
| | Disabled Persons | 1 | 2004 | 72 | 0.210 |
Why?
| | Dietary Fats | 2 | 2017 | 134 | 0.210 |
Why?
| | Egg Proteins | 2 | 2021 | 18 | 0.210 |
Why?
| | Cell Division | 4 | 2006 | 288 | 0.210 |
Why?
| | Disease Models, Animal | 3 | 2019 | 1483 | 0.210 |
Why?
| | Developed Countries | 1 | 2024 | 17 | 0.210 |
Why?
| | Inulin | 1 | 2003 | 11 | 0.210 |
Why?
| | Meat | 3 | 2021 | 55 | 0.210 |
Why?
| | Injections, Intravenous | 2 | 2014 | 130 | 0.210 |
Why?
| | Algorithms | 5 | 2015 | 673 | 0.200 |
Why?
| | Nutrition Surveys | 1 | 2024 | 119 | 0.200 |
Why?
| | Glycine | 4 | 2004 | 78 | 0.200 |
Why?
| | Eukaryotic Initiation Factor-2B | 1 | 2003 | 5 | 0.200 |
Why?
| | Accidental Falls | 1 | 2004 | 107 | 0.200 |
Why?
| | Reference Values | 6 | 2017 | 316 | 0.200 |
Why?
| | Membrane Fusion | 1 | 2022 | 8 | 0.200 |
Why?
| | Pseudomonas aeruginosa | 3 | 2019 | 79 | 0.200 |
Why?
| | Carbohydrate Metabolism | 2 | 2019 | 25 | 0.200 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2002 | 9 | 0.200 |
Why?
| | Weightlessness | 1 | 2002 | 13 | 0.190 |
Why?
| | Vasodilator Agents | 1 | 2003 | 90 | 0.190 |
Why?
| | Tyrosine | 4 | 2022 | 97 | 0.190 |
Why?
| | Splanchnic Circulation | 1 | 2002 | 35 | 0.190 |
Why?
| | Space Flight | 1 | 2002 | 32 | 0.190 |
Why?
| | Pulmonary Surfactants | 1 | 2002 | 17 | 0.190 |
Why?
| | Diet, High-Fat | 2 | 2024 | 230 | 0.190 |
Why?
| | GTP-Binding Proteins | 1 | 2022 | 86 | 0.190 |
Why?
| | Polymers | 1 | 2022 | 51 | 0.190 |
Why?
| | Alaska | 2 | 2020 | 27 | 0.190 |
Why?
| | Reindeer | 1 | 2021 | 3 | 0.180 |
Why?
| | Calorimetry, Indirect | 4 | 2006 | 25 | 0.180 |
Why?
| | Age Factors | 6 | 2017 | 1120 | 0.180 |
Why?
| | Injections, Intramuscular | 3 | 2011 | 57 | 0.180 |
Why?
| | Autophagy | 2 | 2020 | 185 | 0.180 |
Why?
| | Mice, Knockout | 1 | 2024 | 903 | 0.180 |
Why?
| | Myostatin | 1 | 2021 | 8 | 0.180 |
Why?
| | Fasting | 4 | 2020 | 75 | 0.180 |
Why?
| | Lysine | 2 | 2017 | 90 | 0.170 |
Why?
| | Leptin | 1 | 2022 | 148 | 0.170 |
Why?
| | Proteolipids | 1 | 2021 | 10 | 0.170 |
Why?
| | Neoplasms | 1 | 2011 | 1314 | 0.170 |
Why?
| | Health Status | 2 | 2016 | 300 | 0.170 |
Why?
| | Glycogenolysis | 1 | 2020 | 9 | 0.170 |
Why?
| | Severity of Illness Index | 4 | 2017 | 1045 | 0.170 |
Why?
| | Prospective Studies | 5 | 2017 | 2433 | 0.170 |
Why?
| | Plant Proteins | 1 | 2021 | 68 | 0.170 |
Why?
| | Random Allocation | 2 | 2015 | 286 | 0.170 |
Why?
| | Femoral Artery | 3 | 2007 | 104 | 0.170 |
Why?
| | Palmitic Acid | 4 | 2005 | 22 | 0.170 |
Why?
| | Hyperphagia | 1 | 2020 | 9 | 0.170 |
Why?
| | Postoperative Care | 1 | 2021 | 104 | 0.170 |
Why?
| | Analysis of Variance | 6 | 2009 | 558 | 0.160 |
Why?
| | Hypoglycemia | 1 | 2020 | 62 | 0.160 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2020 | 28 | 0.160 |
Why?
| | Breast Feeding | 1 | 2022 | 201 | 0.160 |
Why?
| | Fatty Liver, Alcoholic | 1 | 2020 | 7 | 0.160 |
Why?
| | Enteral Nutrition | 4 | 2006 | 154 | 0.160 |
Why?
| | Preoperative Care | 1 | 2021 | 173 | 0.160 |
Why?
| | RNA, Messenger | 2 | 2022 | 1134 | 0.160 |
Why?
| | Health | 2 | 2012 | 22 | 0.160 |
Why?
| | Fruit | 1 | 2020 | 130 | 0.160 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2022 | 208 | 0.160 |
Why?
| | Mouth | 1 | 2019 | 33 | 0.150 |
Why?
| | Hindlimb | 3 | 2008 | 31 | 0.150 |
Why?
| | Molecular Probe Techniques | 1 | 2019 | 10 | 0.150 |
Why?
| | Radioisotope Dilution Technique | 3 | 2004 | 12 | 0.150 |
Why?
| | Military Medicine | 1 | 2019 | 24 | 0.150 |
Why?
| | Evaluation Studies as Topic | 1 | 2019 | 101 | 0.150 |
Why?
| | Palmitoylcarnitine | 2 | 2011 | 7 | 0.150 |
Why?
| | Intestinal Absorption | 1 | 2019 | 46 | 0.150 |
Why?
| | Altitude Sickness | 2 | 2012 | 8 | 0.150 |
Why?
| | Water | 1 | 2019 | 87 | 0.150 |
Why?
| | Proteome | 1 | 2020 | 175 | 0.150 |
Why?
| | United States | 4 | 2024 | 5215 | 0.150 |
Why?
| | Jejunum | 1 | 2019 | 54 | 0.150 |
Why?
| | Hypoalbuminemia | 1 | 2018 | 4 | 0.150 |
Why?
| | Lung | 1 | 2002 | 479 | 0.150 |
Why?
| | Basal Metabolism | 3 | 2020 | 32 | 0.150 |
Why?
| | HIV Infections | 1 | 2022 | 394 | 0.140 |
Why?
| | Occupational Diseases | 1 | 2019 | 85 | 0.140 |
Why?
| | Liver Neoplasms | 1 | 2022 | 341 | 0.140 |
Why?
| | Cholesterol | 3 | 2013 | 159 | 0.140 |
Why?
| | Alcohol Drinking | 1 | 2020 | 235 | 0.140 |
Why?
| | Inflammation | 4 | 2018 | 649 | 0.140 |
Why?
| | Oxandrolone | 2 | 2011 | 10 | 0.140 |
Why?
| | Intestinal Mucosa | 1 | 2019 | 228 | 0.140 |
Why?
| | Lower Extremity | 2 | 2009 | 97 | 0.140 |
Why?
| | Gastrointestinal Tract | 1 | 2018 | 110 | 0.140 |
Why?
| | Breakfast | 1 | 2017 | 19 | 0.140 |
Why?
| | Oxygen Consumption | 6 | 2019 | 193 | 0.130 |
Why?
| | Hypertension, Pulmonary | 2 | 2012 | 102 | 0.130 |
Why?
| | Injections, Intradermal | 2 | 2007 | 14 | 0.130 |
Why?
| | Circadian Rhythm | 1 | 2017 | 92 | 0.130 |
Why?
| | Quadriceps Muscle | 1 | 2017 | 47 | 0.130 |
Why?
| | Nutrition Assessment | 1 | 2017 | 66 | 0.130 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2017 | 70 | 0.130 |
Why?
| | Mice | 6 | 2024 | 5899 | 0.130 |
Why?
| | Endpoint Determination | 1 | 2016 | 27 | 0.130 |
Why?
| | Athletic Performance | 1 | 2016 | 33 | 0.130 |
Why?
| | Egg Proteins, Dietary | 1 | 2016 | 2 | 0.130 |
Why?
| | Food Quality | 1 | 2016 | 2 | 0.130 |
Why?
| | Physical Fitness | 2 | 2014 | 56 | 0.120 |
Why?
| | Chromatography, Liquid | 2 | 2008 | 245 | 0.120 |
Why?
| | Rest | 2 | 2007 | 60 | 0.120 |
Why?
| | Chronic Disease | 4 | 2017 | 579 | 0.120 |
Why?
| | Hyperemia | 1 | 2015 | 17 | 0.120 |
Why?
| | Forearm | 1 | 2015 | 29 | 0.120 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2008 | 249 | 0.120 |
Why?
| | Tissue Donors | 2 | 2007 | 126 | 0.120 |
Why?
| | Constriction | 2 | 2007 | 8 | 0.120 |
Why?
| | Microdialysis | 2 | 2005 | 18 | 0.120 |
Why?
| | Waist Circumference | 1 | 2015 | 24 | 0.110 |
Why?
| | Capillaries | 2 | 2007 | 53 | 0.110 |
Why?
| | Hand Strength | 1 | 2015 | 25 | 0.110 |
Why?
| | Cross-Sectional Studies | 3 | 2008 | 1677 | 0.110 |
Why?
| | Femoral Vein | 2 | 2005 | 38 | 0.110 |
Why?
| | NF-kappa B | 2 | 2007 | 326 | 0.110 |
Why?
| | Radioactive Tracers | 2 | 2019 | 9 | 0.110 |
Why?
| | Weight Gain | 2 | 2022 | 235 | 0.110 |
Why?
| | Logistic Models | 2 | 2015 | 930 | 0.110 |
Why?
| | Proline | 2 | 2004 | 31 | 0.100 |
Why?
| | Exercise Test | 3 | 2019 | 134 | 0.100 |
Why?
| | Endothelium, Vascular | 1 | 2015 | 263 | 0.100 |
Why?
| | Motor Activity | 3 | 2010 | 227 | 0.100 |
Why?
| | Pulmonary Edema | 2 | 2004 | 15 | 0.100 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 199 | 0.100 |
Why?
| | Walking | 1 | 2014 | 105 | 0.100 |
Why?
| | Carbohydrates | 2 | 2019 | 41 | 0.100 |
Why?
| | Amino Acid Sequence | 2 | 2022 | 576 | 0.100 |
Why?
| | Risk Assessment | 4 | 2017 | 1349 | 0.100 |
Why?
| | Extremities | 1 | 2013 | 31 | 0.100 |
Why?
| | Oxygen | 2 | 2006 | 332 | 0.100 |
Why?
| | Arginase | 1 | 2012 | 35 | 0.100 |
Why?
| | Follow-Up Studies | 4 | 2017 | 2294 | 0.090 |
Why?
| | Altitude | 1 | 2012 | 16 | 0.090 |
Why?
| | Nitric Oxide Synthase | 2 | 2012 | 72 | 0.090 |
Why?
| | Cystic Fibrosis | 2 | 2013 | 160 | 0.090 |
Why?
| | Guidelines as Topic | 1 | 2012 | 111 | 0.090 |
Why?
| | Metabolic Diseases | 1 | 2012 | 48 | 0.090 |
Why?
| | Organ Size | 1 | 2012 | 226 | 0.090 |
Why?
| | Healthcare Disparities | 1 | 2015 | 291 | 0.090 |
Why?
| | Cattle | 2 | 2022 | 197 | 0.090 |
Why?
| | Evidence-Based Medicine | 1 | 2012 | 271 | 0.090 |
Why?
| | Cell Line | 2 | 2004 | 1020 | 0.090 |
Why?
| | Glucose Tolerance Test | 3 | 2010 | 61 | 0.090 |
Why?
| | Pulmonary Artery | 1 | 2012 | 142 | 0.080 |
Why?
| | Parenteral Nutrition | 2 | 2016 | 28 | 0.080 |
Why?
| | Breath Tests | 2 | 2007 | 39 | 0.080 |
Why?
| | Cushing Syndrome | 1 | 2009 | 10 | 0.080 |
Why?
| | Texas | 2 | 2007 | 137 | 0.080 |
Why?
| | Blood Pressure | 2 | 2017 | 525 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2022 | 625 | 0.080 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2010 | 141 | 0.080 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2007 | 140 | 0.080 |
Why?
| | Antiphospholipid Syndrome | 1 | 2009 | 8 | 0.080 |
Why?
| | Cholesterol, VLDL | 1 | 2008 | 3 | 0.070 |
Why?
| | Polysomnography | 2 | 2020 | 76 | 0.070 |
Why?
| | Body Surface Area | 2 | 2006 | 26 | 0.070 |
Why?
| | Institutionalization | 1 | 2008 | 12 | 0.070 |
Why?
| | Cachexia | 1 | 2008 | 28 | 0.070 |
Why?
| | Satiation | 1 | 2008 | 9 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2008 | 56 | 0.070 |
Why?
| | Muscle Strength Dynamometer | 1 | 2008 | 12 | 0.070 |
Why?
| | Gene Expression Regulation | 4 | 2010 | 1004 | 0.070 |
Why?
| | Fontan Procedure | 1 | 2009 | 66 | 0.070 |
Why?
| | Linear Models | 2 | 2009 | 288 | 0.070 |
Why?
| | Parenteral Nutrition Solutions | 2 | 2004 | 8 | 0.070 |
Why?
| | RNA, Transfer | 1 | 2007 | 13 | 0.070 |
Why?
| | Citric Acid Cycle | 1 | 2007 | 16 | 0.070 |
Why?
| | Solutions | 2 | 2004 | 25 | 0.070 |
Why?
| | Sodium Bicarbonate | 1 | 2007 | 8 | 0.070 |
Why?
| | Ketoconazole | 1 | 2007 | 10 | 0.070 |
Why?
| | Electrolytes | 2 | 2004 | 26 | 0.070 |
Why?
| | Sleep | 2 | 2020 | 191 | 0.070 |
Why?
| | Space Simulation | 1 | 2007 | 2 | 0.070 |
Why?
| | Placebos | 2 | 2004 | 83 | 0.070 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2009 | 96 | 0.070 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 1888 | 0.070 |
Why?
| | Adenosine Triphosphate | 1 | 2008 | 234 | 0.070 |
Why?
| | Saliva | 1 | 2007 | 56 | 0.070 |
Why?
| | Tandem Mass Spectrometry | 1 | 2008 | 255 | 0.070 |
Why?
| | Gait | 1 | 2008 | 88 | 0.070 |
Why?
| | Acute Disease | 2 | 2019 | 384 | 0.070 |
Why?
| | Virus Latency | 1 | 2007 | 53 | 0.070 |
Why?
| | Trauma Severity Indices | 1 | 2007 | 51 | 0.060 |
Why?
| | Sex Factors | 2 | 2020 | 735 | 0.060 |
Why?
| | Cell Compartmentation | 1 | 2006 | 9 | 0.060 |
Why?
| | RNA | 1 | 2007 | 174 | 0.060 |
Why?
| | Styrenes | 1 | 2006 | 2 | 0.060 |
Why?
| | Siloxanes | 1 | 2006 | 2 | 0.060 |
Why?
| | Risk Factors | 4 | 2019 | 3971 | 0.060 |
Why?
| | Occlusive Dressings | 1 | 2006 | 6 | 0.060 |
Why?
| | Osmolar Concentration | 2 | 2003 | 61 | 0.060 |
Why?
| | APACHE | 1 | 2006 | 25 | 0.060 |
Why?
| | Administration, Topical | 1 | 2006 | 62 | 0.060 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2006 | 35 | 0.060 |
Why?
| | Hepatomegaly | 1 | 2006 | 7 | 0.060 |
Why?
| | Bandages | 1 | 2006 | 27 | 0.060 |
Why?
| | Methods | 1 | 2005 | 53 | 0.060 |
Why?
| | Carbohydrate Sequence | 1 | 2005 | 7 | 0.060 |
Why?
| | Anti-Infective Agents, Local | 1 | 2006 | 29 | 0.060 |
Why?
| | Anti-Inflammatory Agents | 1 | 2007 | 166 | 0.060 |
Why?
| | Injury Severity Score | 1 | 2006 | 165 | 0.060 |
Why?
| | Creatinine | 1 | 2006 | 156 | 0.060 |
Why?
| | Reference Standards | 1 | 2005 | 51 | 0.060 |
Why?
| | Infusions, Intra-Arterial | 1 | 2005 | 13 | 0.060 |
Why?
| | Pressure Ulcer | 1 | 2005 | 16 | 0.060 |
Why?
| | Fibrinolysis | 1 | 2005 | 5 | 0.060 |
Why?
| | Life Style | 1 | 2006 | 148 | 0.060 |
Why?
| | Body Water | 1 | 2005 | 26 | 0.060 |
Why?
| | Arteries | 2 | 2004 | 93 | 0.060 |
Why?
| | Hematocrit | 1 | 2005 | 42 | 0.060 |
Why?
| | Blood Coagulation Tests | 1 | 2005 | 18 | 0.060 |
Why?
| | Milk | 1 | 2006 | 84 | 0.060 |
Why?
| | Fluorocarbons | 1 | 2005 | 59 | 0.060 |
Why?
| | Stress, Psychological | 1 | 2007 | 275 | 0.060 |
Why?
| | Osteoporosis | 1 | 2006 | 157 | 0.060 |
Why?
| | Practice Guidelines as Topic | 1 | 2008 | 498 | 0.060 |
Why?
| | Ecchymosis | 1 | 2004 | 8 | 0.060 |
Why?
| | Signal Transduction | 3 | 2020 | 1724 | 0.060 |
Why?
| | Blood Specimen Collection | 1 | 2004 | 35 | 0.060 |
Why?
| | Myocardial Infarction | 1 | 2009 | 449 | 0.060 |
Why?
| | Biological Transport, Active | 1 | 2004 | 29 | 0.050 |
Why?
| | Muscle Fatigue | 1 | 2004 | 15 | 0.050 |
Why?
| | Locomotion | 1 | 2004 | 80 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 778 | 0.050 |
Why?
| | Hematoma | 1 | 2004 | 67 | 0.050 |
Why?
| | Biopsy, Needle | 1 | 2004 | 181 | 0.050 |
Why?
| | Catheterization | 1 | 2004 | 94 | 0.050 |
Why?
| | Culture Media | 1 | 2004 | 96 | 0.050 |
Why?
| | Interleukin-18 | 1 | 2024 | 26 | 0.050 |
Why?
| | Respiratory Function Tests | 1 | 2004 | 90 | 0.050 |
Why?
| | Albumins | 1 | 2004 | 29 | 0.050 |
Why?
| | Physical Education and Training | 1 | 2004 | 23 | 0.050 |
Why?
| | Iontophoresis | 1 | 2003 | 13 | 0.050 |
Why?
| | Pilocarpine | 1 | 2003 | 20 | 0.050 |
Why?
| | Amino Acid Transport Systems | 1 | 2003 | 5 | 0.050 |
Why?
| | Equipment Design | 1 | 2004 | 287 | 0.050 |
Why?
| | Cell Count | 1 | 2004 | 143 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2024 | 114 | 0.050 |
Why?
| | Glutamic Acid | 1 | 2004 | 111 | 0.050 |
Why?
| | Injections, Intra-Arterial | 1 | 2003 | 13 | 0.050 |
Why?
| | Adaptation, Physiological | 1 | 2004 | 111 | 0.050 |
Why?
| | Nitric Oxide Donors | 1 | 2003 | 9 | 0.050 |
Why?
| | Nitroprusside | 1 | 2003 | 10 | 0.050 |
Why?
| | Regression Analysis | 1 | 2004 | 400 | 0.050 |
Why?
| | Ovarian Neoplasms | 1 | 2007 | 455 | 0.050 |
Why?
| | Cough | 1 | 2003 | 55 | 0.050 |
Why?
| | Obesity, Morbid | 1 | 2004 | 86 | 0.050 |
Why?
| | Computer Simulation | 1 | 2004 | 285 | 0.050 |
Why?
| | Blood Circulation | 1 | 2003 | 9 | 0.050 |
Why?
| | Time | 1 | 2003 | 29 | 0.050 |
Why?
| | Coloring Agents | 1 | 2003 | 68 | 0.050 |
Why?
| | Indocyanine Green | 1 | 2003 | 29 | 0.050 |
Why?
| | Hydroxyproline | 1 | 2003 | 19 | 0.050 |
Why?
| | Ventricular Dysfunction | 1 | 2003 | 11 | 0.050 |
Why?
| | Carbazoles | 1 | 2003 | 18 | 0.050 |
Why?
| | HIV Envelope Protein gp41 | 1 | 2022 | 5 | 0.050 |
Why?
| | Body Constitution | 1 | 2002 | 12 | 0.050 |
Why?
| | Weightlessness Countermeasures | 1 | 2002 | 2 | 0.050 |
Why?
| | Transposition of Great Vessels | 1 | 2003 | 26 | 0.050 |
Why?
| | Cell Membrane | 1 | 2003 | 238 | 0.050 |
Why?
| | Drug Combinations | 1 | 2003 | 136 | 0.050 |
Why?
| | Fish Oils | 1 | 2002 | 14 | 0.050 |
Why?
| | Blood Proteins | 1 | 2023 | 84 | 0.050 |
Why?
| | Linoleic Acid | 1 | 2002 | 16 | 0.050 |
Why?
| | Phosphatidylcholines | 1 | 2002 | 27 | 0.050 |
Why?
| | Endotoxins | 1 | 2002 | 23 | 0.050 |
Why?
| | Ear | 1 | 2002 | 15 | 0.050 |
Why?
| | Kidney Diseases | 1 | 2005 | 230 | 0.050 |
Why?
| | Microspheres | 1 | 2002 | 20 | 0.050 |
Why?
| | Leukocyte Count | 1 | 2002 | 71 | 0.050 |
Why?
| | Fat Emulsions, Intravenous | 1 | 2002 | 13 | 0.050 |
Why?
| | Lactates | 1 | 2022 | 30 | 0.050 |
Why?
| | Communicable Disease Control | 1 | 2022 | 37 | 0.050 |
Why?
| | Carotid Arteries | 1 | 2002 | 77 | 0.050 |
Why?
| | Ribosomal Proteins | 1 | 2022 | 24 | 0.050 |
Why?
| | Drug Synergism | 1 | 2002 | 147 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2004 | 871 | 0.050 |
Why?
| | Thinness | 2 | 2016 | 45 | 0.040 |
Why?
| | Peptides | 1 | 2022 | 239 | 0.040 |
Why?
| | Neutrophils | 1 | 2002 | 148 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 2022 | 168 | 0.040 |
Why?
| | Fatty Liver | 1 | 2002 | 141 | 0.040 |
Why?
| | Gene Expression | 1 | 2003 | 618 | 0.040 |
Why?
| | Food | 1 | 2020 | 67 | 0.040 |
Why?
| | Orthopedic Procedures | 1 | 2021 | 70 | 0.040 |
Why?
| | Ceramides | 1 | 2020 | 33 | 0.040 |
Why?
| | Dexamethasone | 1 | 2022 | 434 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 257 | 0.040 |
Why?
| | T-Lymphocytes | 1 | 2022 | 318 | 0.040 |
Why?
| | Protein Kinases | 1 | 2020 | 73 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2020 | 168 | 0.040 |
Why?
| | Occupational Health | 1 | 2019 | 66 | 0.040 |
Why?
| | Capillary Permeability | 1 | 2018 | 29 | 0.040 |
Why?
| | Rats, Zucker | 2 | 2010 | 73 | 0.040 |
Why?
| | Apoptosis | 1 | 2003 | 1120 | 0.040 |
Why?
| | Artifacts | 1 | 2018 | 53 | 0.030 |
Why?
| | Body Weights and Measures | 1 | 2017 | 18 | 0.030 |
Why?
| | Hunger | 1 | 2017 | 15 | 0.030 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2004 | 570 | 0.030 |
Why?
| | Animal Structures | 1 | 2017 | 3 | 0.030 |
Why?
| | Clinical Chemistry Tests | 1 | 2017 | 3 | 0.030 |
Why?
| | Withholding Treatment | 1 | 2017 | 19 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 580 | 0.030 |
Why?
| | Blood Gas Analysis | 1 | 2017 | 29 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 725 | 0.030 |
Why?
| | Indicator Dilution Techniques | 1 | 2017 | 13 | 0.030 |
Why?
| | Venae Cavae | 1 | 2017 | 9 | 0.030 |
Why?
| | Crosses, Genetic | 1 | 2017 | 34 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2017 | 113 | 0.030 |
Why?
| | Sus scrofa | 1 | 2017 | 39 | 0.030 |
Why?
| | Mutation | 1 | 2022 | 1331 | 0.030 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2017 | 65 | 0.030 |
Why?
| | Glycogen | 2 | 2010 | 44 | 0.030 |
Why?
| | Caffeine | 1 | 2016 | 69 | 0.030 |
Why?
| | Catheterization, Central Venous | 1 | 2017 | 79 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2020 | 805 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2016 | 126 | 0.030 |
Why?
| | Research Design | 1 | 2017 | 368 | 0.030 |
Why?
| | Pregnancy | 1 | 2022 | 2642 | 0.030 |
Why?
| | Multienzyme Complexes | 2 | 2006 | 43 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 2016 | 171 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 938 | 0.030 |
Why?
| | Cardiac Catheterization | 2 | 2009 | 228 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2021 | 1065 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 446 | 0.030 |
Why?
| | Octreotide | 1 | 2013 | 9 | 0.030 |
Why?
| | Subcutaneous Fat, Abdominal | 1 | 2013 | 7 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2015 | 186 | 0.030 |
Why?
| | Intra-Abdominal Fat | 1 | 2013 | 20 | 0.030 |
Why?
| | Ubiquitin | 2 | 2003 | 70 | 0.020 |
Why?
| | Medicare | 1 | 2015 | 281 | 0.020 |
Why?
| | Health Status Disparities | 1 | 2015 | 218 | 0.020 |
Why?
| | Rats | 2 | 2010 | 3228 | 0.020 |
Why?
| | Colorado | 1 | 2012 | 22 | 0.020 |
Why?
| | Age of Onset | 1 | 2012 | 109 | 0.020 |
Why?
| | Acetyl-CoA Carboxylase | 1 | 2010 | 13 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2012 | 283 | 0.020 |
Why?
| | Sciatic Nerve | 1 | 2010 | 24 | 0.020 |
Why?
| | Amino-Acid N-Acetyltransferase | 1 | 2010 | 2 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 234 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2010 | 106 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 370 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2012 | 6694 | 0.020 |
Why?
| | Protein-Energy Malnutrition | 1 | 2009 | 16 | 0.020 |
Why?
| | Chest Pain | 1 | 2009 | 55 | 0.020 |
Why?
| | Down-Regulation | 1 | 2010 | 348 | 0.020 |
Why?
| | Cardiac Surgical Procedures | 1 | 2012 | 329 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2011 | 756 | 0.020 |
Why?
| | Movement | 1 | 2008 | 83 | 0.020 |
Why?
| | Patient Discharge | 1 | 2010 | 320 | 0.020 |
Why?
| | Thermogenesis | 1 | 2008 | 31 | 0.020 |
Why?
| | Blood Chemical Analysis | 1 | 2007 | 26 | 0.020 |
Why?
| | Electrocardiography | 1 | 2009 | 273 | 0.020 |
Why?
| | Coronary Angiography | 1 | 2009 | 367 | 0.020 |
Why?
| | Diglycerides | 1 | 2006 | 10 | 0.020 |
Why?
| | Lipolysis | 1 | 2006 | 11 | 0.020 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2006 | 34 | 0.020 |
Why?
| | Aerobiosis | 1 | 2006 | 13 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2006 | 152 | 0.020 |
Why?
| | Anticoagulants | 1 | 2009 | 276 | 0.010 |
Why?
| | Cohort Studies | 1 | 2010 | 1576 | 0.010 |
Why?
| | Hematinics | 1 | 2005 | 15 | 0.010 |
Why?
| | Phosphorylation | 1 | 2006 | 536 | 0.010 |
Why?
| | Surgical Procedures, Operative | 1 | 2006 | 66 | 0.010 |
Why?
| | Erythropoietin | 1 | 2005 | 50 | 0.010 |
Why?
| | Glomerular Filtration Rate | 1 | 2005 | 126 | 0.010 |
Why?
| | Drug Utilization | 1 | 2005 | 77 | 0.010 |
Why?
| | Mice, Inbred ICR | 1 | 2004 | 25 | 0.010 |
Why?
| | Hindlimb Suspension | 1 | 2004 | 37 | 0.010 |
Why?
| | Gastric Bypass | 1 | 2004 | 21 | 0.010 |
Why?
| | Diaphragm | 1 | 2004 | 33 | 0.010 |
Why?
| | 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) | 1 | 2003 | 2 | 0.010 |
Why?
| | Veins | 1 | 2004 | 74 | 0.010 |
Why?
| | Bronchiectasis | 1 | 2003 | 8 | 0.010 |
Why?
| | Complement System Proteins | 1 | 2003 | 32 | 0.010 |
Why?
| | Forced Expiratory Volume | 1 | 2003 | 52 | 0.010 |
Why?
| | Caspase 3 | 1 | 2003 | 91 | 0.010 |
Why?
| | Acidosis | 1 | 2003 | 41 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2005 | 490 | 0.010 |
Why?
| | Immunoglobulin E | 1 | 2003 | 92 | 0.010 |
Why?
| | Extracellular Space | 1 | 2003 | 38 | 0.010 |
Why?
| | Food Additives | 1 | 2003 | 7 | 0.010 |
Why?
| | Protein Array Analysis | 1 | 2003 | 24 | 0.010 |
Why?
| | Infant | 1 | 2012 | 3709 | 0.010 |
Why?
| | Caspases | 1 | 2003 | 101 | 0.010 |
Why?
| | Organic Chemicals | 1 | 2003 | 15 | 0.010 |
Why?
| | Wound Infection | 1 | 2003 | 32 | 0.010 |
Why?
| | Cysteine Endopeptidases | 1 | 2003 | 65 | 0.010 |
Why?
| | Comorbidity | 1 | 2004 | 637 | 0.010 |
Why?
| | Diuresis | 1 | 2002 | 15 | 0.010 |
Why?
| | Norepinephrine | 1 | 2002 | 106 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2003 | 412 | 0.010 |
Why?
| | Stroke Volume | 1 | 2003 | 148 | 0.010 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2003 | 137 | 0.010 |
Why?
| | Recurrence | 1 | 2003 | 680 | 0.010 |
Why?
| | Receptors, Androgen | 1 | 2002 | 48 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2003 | 641 | 0.010 |
Why?
| | Prostate | 1 | 2002 | 116 | 0.010 |
Why?
| | Incidence | 1 | 2004 | 1096 | 0.010 |
Why?
| | Blotting, Western | 1 | 2002 | 587 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2003 | 1028 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2003 | 1140 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2003 | 1099 | 0.010 |
Why?
|
|
Wolfe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|